All articles by Divya Tirumalaraju

1. Roche and UCB partner to develop antibody therapy for Alzheimer’s

   Roche and its unit Genentech have agreed to a global, exclusive licence agreement with Belgian company UCB to develop and…
   Read More…

   30 Jul
2. Hetero launches generic favipiravir to treat Covid-19 in India

   India-based Hetero Labs has launched a generic version of antiviral drug favipiravir, under the brand name Favivir, to treat Covid-19…
   Read More…

   30 Jul
3. US DFC to offer $765m loan to support Kodak Pharmaceuticals

   The US International Development Finance Corporation (DFC) has signed a letter of interest (LOI) to offer a $765m loan to…
   Read More…

   29 Jul
4. Health Canada authorises remdesivir as first Covid-19 treatment

   Health Canada has granted conditional approval to Gilead Sciences’ remdesivir (Veklury) to treat patients with severe Covid-19 who have pneumonia…
   Read More…

   29 Jul
5. Sanofi and GSK to supply Covid-19 vaccine doses to UK

   Sanofi and GlaxoSmithKline (GSK) have signed an agreement with the UK Government to supply up to 60 million doses of…
   Read More…

   29 Jul
6. Sandoz partners with Austria to boost antibiotics production

   Swiss pharmaceutical company Novartis unit Sandoz has partnered with the Austrian Government to boost integrated antibiotics production in Europe. Sandoz…
   Read More…

   28 Jul
7. Emergent expands Covid-19 vaccine manufacturing deal with AstraZeneca

   Emergent BioSolutions has entered into an agreement valued at approximately $174m for large-scale commercial production of drug substance for AstraZeneca…
   Read More…

   28 Jul
8. Biocon’s itolizumab fails to be part of Covid-19 management protocols

   The National Task Force for Covid-19 in India has denied the inclusion of Biocon’s itolizumab in its clinical management protocols…
   Read More…

   28 Jul
9. Indivior to pay $600m to settle opioid drug marketing claims

   Indivior has reached an agreement to pay $600m to settle US claims that the company had run an illegal scheme…
   Read More…

   27 Jul
10. AstraZeneca signs $6bn worth cancer asset deal with Daiichi Sankyo

    AstraZeneca has signed a new agreement to develop and commercialise Japanese company Daiichi Sankyo’s trophoblast cell-surface antigen 2 (TROP2)-directed antibody…
    Read More…

    27 Jul